

Dexmedetomidine and Its Use in Different Routes – A Review

**K Sohith Reddy,^[1] Dr. Major Priyank Sen,^[2] Dr. Sanjay Ashwamedh Kshirsagar,^[3]
Dr. Hemangi Yashwant Jadhav,^[4] Dr. Safdhar Hasmi. R^[5]**

1. Department of Computational Biology, Saveetha School of Engineering, SIMATS University, Chennai, Tamilnadu, India.
2. Dental officer specialist Orthodontics Military dental centre Gwalior, Madhya Pradesh, India.
3. Specialist Anaesthesia, Anaesthesia and ICU, Latifa Hospital, AL Jadaff, Dubai, UAE
4. Consultant, MDS in Oral and Maxillofacial pathology and oral microbiology, Thane, India.
5. Senior resident, Department of Anaesthesiology, King George Medical University, Lucknow, UP, India.

***Corresponding Address:**

Dr. Safdhar Hasmi. R, Senior Resident, Department of Anaesthesiology, , King George Medical University, India. **Email id:** safdharlorzi@gmail.com

Abstract:

Dexmedetomidine is a highly versatile alpha-2 adrenergic agonist with sedative, analgesic, and anxiolytic properties, making it an invaluable agent in the field of anaesthesia and critical care. Its efficacy and safety profile have led to its use via various routes of administration, catering to different patient populations and clinical scenarios. In intensive care units (ICUs), dexmedetomidine infusion has emerged as a cornerstone for sedation due to its ability to provide sedation while maintaining a patient's ability to interact and cooperate during procedures, facilitating early extubation and reducing the risk of delirium. The sublingual route of dexmedetomidine administration has gained attention for preoperative anxiolysis, offering a convenient and effective alternative to traditional sedatives. In the realm of regional anaesthesia and pain management, dexmedetomidine delivered via intrathecal infusion has demonstrated efficacy in perioperative pain control, reducing opioid requirements and improving postoperative outcomes.

Key words: Analgesia, Anxiolysis, Dexmedetomidine, Sedation, Versatility

Introduction:

Dexmedetomidine, an alpha-2 adrenergic agonist, has revolutionized the landscape of sedation and analgesia in clinical practice. Its unique pharmacological profile, characterized by sedative, analgesic, and anxiolytic properties with minimal respiratory depression, has made it a preferred choice in various medical settings. This introduction delves into the pharmacology, mechanisms of action, and clinical applications of dexmedetomidine, highlighting its versatility and expanding role in modern anaesthesia and critical care. Pharmacologically, dexmedetomidine acts selectively on alpha-2 adrenergic receptors in the central nervous system, primarily in the locus coeruleus. By inhibiting the release of norepinephrine, it leads to sedation, analgesia, and reduced sympathetic outflow without significant depression of respiratory drive, distinguishing it from traditional sedative-hypnotic agents like benzodiazepines and opioids. This unique mechanism underpins its favorable safety profile, particularly in patients with compromised respiratory function or those requiring prolonged sedation.

The clinical applications of dexmedetomidine span a wide spectrum of medical specialties. In intensive care units (ICUs), dexmedetomidine infusion has gained popularity as a first-line

agent for sedation in mechanically ventilated patients. Its ability to provide sedation while preserving spontaneous breathing and cognitive function is particularly advantageous in critically ill patients, facilitating early weaning from mechanical ventilation and reducing the incidence of delirium compared to traditional sedatives. ^[1,2] Outside the ICU, dexmedetomidine has found utility in preoperative and intraoperative settings. Sublingual dexmedetomidine has emerged as a promising option for preoperative anxiolysis, offering rapid onset and anxiolytic effects without the need for intravenous access. During surgical procedures, dexmedetomidine can be used as an adjunct to general anaesthesia to reduce the requirements for volatile anaesthetics and opioids, leading to smoother emergence and improved postoperative pain management. Paediatric anaesthesia and procedural sedation represent another area where dexmedetomidine shines. Intranasal dexmedetomidine has been investigated for its efficacy in providing sedation and analgesia during minor procedures in children, offering a non-invasive and well-tolerated alternative to intravenous sedatives. Its ability to achieve sedation without significant respiratory depression is particularly advantageous in paediatric patients with underlying respiratory conditions. ^[3]

In the realm of pain management, dexmedetomidine has expanded beyond its role as a sedative. Transdermal patches delivering dexmedetomidine have shown promise in providing prolonged analgesia postoperatively, reducing the need for systemic opioids and their associated side effects. Intrathecal infusion of dexmedetomidine has also been explored for its analgesic properties, especially in patients undergoing spinal surgeries or experiencing refractory pain. Moreover, dexmedetomidine's versatility extends to procedural sedation in non-operating room settings. Inhalational dexmedetomidine has been studied for its use in conscious sedation during procedures such as magnetic resonance imaging (MRI), offering a safe and effective sedative option with rapid onset and recovery. ^[4]

Intravenous dexmedetomidine for sedation and other purposes:

For sedation in ICUs, the initial loading dose of intravenous dexmedetomidine is commonly administered at a rate of 0.2 to 0.7 micrograms per kilogram of body weight over 10 to 20 minutes. This loading dose is followed by a maintenance infusion typically ranging from 0.2 to 1.4 micrograms per kilogram per hour. The infusion rate is titrated based on the patient's sedation level, aiming for a Richmond Agitation-Sedation Scale (RASS) score of -2 to 0 for light to moderate sedation. In cases of agitation or delirium in ICU patients, dexmedetomidine can be administered at a lower initial loading dose (e.g., 0.2 to 0.5 micrograms per kilogram over 10 minutes) followed by a reduced maintenance infusion rate (e.g., 0.2 to 0.5 micrograms per kilogram per hour). The goal is to provide calming sedation without over-sedation, which can exacerbate delirium or prolong recovery.

In preoperative settings, dexmedetomidine is often administered as an intravenous infusion at a loading dose of 0.5 to 1 microgram per kilogram over 10 to 20 minutes. This is followed by a maintenance infusion at a rate of 0.2 to 0.7 micrograms per kilogram per hour. The goal is to achieve adequate anxiolysis and sedation before induction of anaesthesia, with careful titration to maintain patient comfort and cooperation.

For procedural sedation, intravenous dexmedetomidine can be given as a loading dose of 1 microgram per kilogram over 10 minutes, followed by a maintenance infusion at 0.2 to 0.7

micrograms per kilogram per hour during the procedure. The infusion rate may be adjusted based on the patient's response and the duration of the procedure, aiming to achieve the desired sedation level while ensuring patient safety and comfort.

As an adjunct to general anaesthesia, dexmedetomidine is typically given as a loading dose of 0.5 to 1 microgram per kilogram over 10 to 20 minutes before induction, followed by a maintenance infusion at 0.2 to 0.7 micrograms per kilogram per hour during the surgical procedure. This adjunctive therapy helps reduce the requirements for volatile anesthetics and opioids, contributing to smoother emergence and improved postoperative pain control. [5,6] The injection Dexmedetomidine is also used for the intravenous regional anaesthesia. [7]

It's essential to note that these dosing guidelines serve as general recommendations, and actual dosages should be individualized based on factors such as the patient's hemodynamic status, age, comorbidities, and concurrent medications. Continuous monitoring of vital signs, sedation levels, and adverse effects is paramount to ensure safe and effective use of dexmedetomidine across different clinical settings.

Nebulized dexmedetomidine and its usages:

Nebulized dexmedetomidine represents a novel approach to delivering sedation and analgesia, particularly in scenarios where intravenous access may be challenging or where localized effects are desired. This discussion explores the uses of nebulized dexmedetomidine and outlines recommended dosages for different clinical applications. This technique may overcome the pressure response due to laryngoscopy. [8]

Nebulized dexmedetomidine can be used for procedural sedation in non-intubated patients undergoing minor procedures such as bronchoscopy, endoscopy, or wound care. It offers a non-invasive route of administration, avoiding the need for intravenous access and reducing the risk of systemic side effects. [9]

In patients with respiratory distress or agitation, nebulized dexmedetomidine can provide anxiolysis and mild sedation while preserving respiratory drive. This is particularly beneficial in settings such as emergency departments or critical care units where rapid sedation without compromising ventilation is essential.

Nebulized dexmedetomidine has been explored as an adjunctive therapy for pain management, especially in conditions such as acute exacerbations of chronic pain or postoperative pain. Its localized analgesic effects can complement systemic analgesics, potentially reducing overall opioid requirements. For procedural sedation, the recommended dosage of nebulized dexmedetomidine is typically 1 to 2 micrograms per kilogram of body weight, administered over 10 to 15 minutes before the procedure. The dosage may be adjusted based on the patient's response and the desired level of sedation. In cases of respiratory distress or agitation, a lower dose of nebulized dexmedetomidine ranging from 0.5 to 1 microgram per kilogram may be sufficient to achieve anxiolysis and mild sedation. This lower dose helps avoid over-sedation and respiratory depression. [10]

As an adjunct for pain management, nebulized dexmedetomidine can be administered at a dose of 1 to 2 micrograms per kilogram, either as a single dose or as intermittent doses based on

pain severity and response. It can be combined with systemic analgesics for synergistic pain relief.

It's important to note that dosages may vary based on the specific nebulization system used, the concentration of dexmedetomidine solution, and individual patient factors such as age, comorbidities, and concurrent medications. Continuous monitoring of respiratory status, sedation levels, and adverse effects is essential during nebulized dexmedetomidine administration to ensure safety and efficacy.

Dexmedetomidine in peripheral nerve blocks:

Dexmedetomidine, a highly selective alpha-2 adrenergic agonist, has garnered attention for its adjunctive role in peripheral nerve blocks. When added to local anesthetics, dexmedetomidine can prolong the duration of analgesia, reduce the need for opioids, and improve postoperative pain management. This discussion focuses on the use of dexmedetomidine in peripheral nerve blocks and provides guidance on dosages for different nerve block techniques. The mechanism of action of dexmedetomidine is it acts locally at peripheral nerve terminals, where it potentiates the effects of local anesthetics. By binding to alpha-2 adrenergic receptors, it inhibits the release of norepinephrine and decreases the excitability of nociceptive neurons, leading to enhanced analgesia and prolonged duration of nerve block. ^[11]

Use of dexmedetomidine in common peripheral nerve and plexus blocks:

Brachial plexus blocks: In brachial plexus blocks for upper limb surgeries, dexmedetomidine can be added to the local anesthetic solution. Typical dosages range from 0.5 to 1 microgram per kilogram of body weight as an adjuvant to the local anesthetic agent. This combination prolongs the duration of sensory and motor blockade, providing extended postoperative analgesia. ^[12]

Femoral nerve blocks: For femoral nerve blocks in lower limb surgeries, dexmedetomidine can be added at a dose of 0.5 to 1 microgram per kilogram to the local anesthetic solution. This adjunctive therapy extends the duration of analgesia, reduces opioid consumption, and improves patient satisfaction with pain control after surgery. ^[13]

Intercostal nerve blocks: In thoracic surgeries or postoperative pain management, intercostal nerve blocks with dexmedetomidine can be performed. The recommended dosage of dexmedetomidine is typically 0.25 to 0.5 micrograms per kilogram as an adjunct to the local anesthetic, providing effective analgesia and minimizing systemic side effects.

Sciatic nerve blocks: Dexmedetomidine can also be used in sciatic nerve blocks for lower limb procedures. The dosage ranges from 0.5 to 1 microgram per kilogram, added to the local anesthetic solution. This combination results in prolonged pain relief and improved patient comfort during the postoperative period.

Considerations and monitoring: When using dexmedetomidine in peripheral nerve blocks, careful monitoring of vital signs, sedation levels, and potential side effects is essential. Patients should be monitored for bradycardia, hypotension, and respiratory depression, especially when higher doses are used. Titration of dexmedetomidine dosage based on patient factors such as

age, comorbidities, and concurrent medications is recommended to optimize analgesic effects while minimizing adverse events.

Oral dexmedetomidine as a part of anaesthesia:

Studies exploring the use of oral dexmedetomidine are relatively limited compared to its well-established intravenous administration. However, there have been some investigations into the oral formulation of dexmedetomidine for sedation and other purposes. It's essential to note that the development and utilization of oral dexmedetomidine are still in early stages, and more robust clinical data are needed to establish its efficacy and safety. Here are a few studies that have explored oral dexmedetomidine:

Oral dexmedetomidine for premedication in children: A study published in the journal evaluated the use of oral dexmedetomidine in a dose of 4mcg/kg as a premedication agent in children. The study compared the sedative effects and safety profile of oral dexmedetomidine with oral midazolam in paediatric patients undergoing elective surgeries. Results showed that oral dexmedetomidine provided effective sedation with a favourable safety profile, making it a potential alternative to traditional premedication agents in paediatric anaesthesia. ^[14]

Oral dexmedetomidine for procedural sedation: Another study, published in a journal, investigated the use of oral dexmedetomidine for procedural sedation in adults undergoing minor surgical procedures. ^[15] The study assessed the sedative and analgesic effects of oral dexmedetomidine compared to intravenous dexmedetomidine and placebo. While the results showed promising sedative properties of oral dexmedetomidine, further research is needed to establish its efficacy in procedural sedation.

Pharmacokinetics of oral dexmedetomidine: Pharmacokinetic studies have also been conducted to evaluate the absorption, distribution, metabolism, and elimination of oral dexmedetomidine. These studies aim to understand the bioavailability and pharmacokinetic profile of oral dexmedetomidine compared to intravenous administration, providing valuable insights into its potential clinical use.

Oral dexmedetomidine for chronic pain management: Some ongoing research focuses on the use of oral dexmedetomidine for chronic pain management. This includes studies exploring its role as an adjuvant to systemic analgesics or as a standalone therapy for certain types of chronic pain conditions. These studies aim to determine the efficacy, safety, and optimal dosing of oral dexmedetomidine in chronic pain management.

While these studies indicate the potential of oral dexmedetomidine in various clinical scenarios, including premedication, procedural sedation, and chronic pain management, it's important to emphasize that more extensive clinical trials are needed to establish its place in clinical practice. Factors such as dosing accuracy, bioavailability, and patient response require further investigation to ensure safe and effective use of oral dexmedetomidine.

Dexmedetomidine through nasal route as a part of anaesthesia:

Several studies have explored the use of nasal dexmedetomidine for sedation and analgesia in various clinical scenarios.

Nasal dexmedetomidine for paediatric sedation: A study investigated the efficacy and safety of nasal dexmedetomidine for sedation in paediatric patients undergoing MRI procedures. The results showed that nasal dexmedetomidine provided effective sedation with minimal adverse effects, making it a valuable option for paediatric sedation in imaging settings.^[16]

A study compared the sedative effects and patient satisfaction between nasal and intravenous dexmedetomidine for procedural sedation in adults. The dose was ranged from 1 to 2 micrograms per kilogram of body weight, administration. The findings indicated that nasal dexmedetomidine was as effective as intravenous administration in achieving sedation and analgesia, with a similar safety profile and higher patient satisfaction due to the non-invasive route of administration.^[17]

Nasal dexmedetomidine for preoperative anxiolysis: In a study, nasal dexmedetomidine was evaluated for preoperative anxiolysis in adult patients. The results demonstrated that nasal dexmedetomidine effectively reduced preoperative anxiety levels and improved patient comfort before induction of anaesthesia, highlighting its potential as a premedication agent.^[18,19] These studies collectively support the efficacy and safety of nasal dexmedetomidine for sedation and anxiolysis in both paediatric and adult populations, particularly in settings where intravenous access may be challenging or where a non-invasive sedation option is preferred. However, further research and clinical trials are needed to establish standardized dosing regimens, optimize sedation protocols, and explore additional applications of nasal dexmedetomidine in clinical practice.

Nasal dexmedetomidine in emergency department sedation:

A study examined the use of nasal dexmedetomidine for sedation in the emergency department. The findings showed that nasal dexmedetomidine provided rapid and effective sedation for minor procedures and imaging studies, with minimal respiratory depression and a high level of patient cooperation.^[20]

Intrathecal dexmedetomidine use in anaesthesia practice:

The intrathecal route of administering dexmedetomidine involves delivering the medication directly into the subarachnoid space, near the spinal cord. This method allows for targeted spinal anaesthesia and analgesia, particularly useful in surgeries involving the lower abdomen, pelvis, or lower extremities. Dosages of intrathecal dexmedetomidine vary depending on the specific procedure, patient characteristics, and desired level of anaesthesia, typically ranging from 1 to 10 micrograms. It is often administered along with a local anesthetic agent such as bupivacaine or ropivacaine.

Intrathecal dexmedetomidine finds application in surgical anaesthesia, serving as an adjunct to local anesthetics for procedures like lower limb orthopedic surgeries, cesarean sections, and urological surgeries. Additionally, it provides prolonged postoperative analgesia, reducing the need for opioids and improving pain management in the immediate postoperative period. While less common, intrathecal dexmedetomidine may also be considered for chronic pain management, although this usage requires specialized expertise and careful patient selection.

One of the key benefits of intrathecal dexmedetomidine is its ability to enhance the analgesic effect of local anesthetics, resulting in prolonged and more effective pain relief during and after surgery. This adjunct also contributes to a reduction in opioid use, mitigating opioid-related side effects such as respiratory depression, sedation, and gastrointestinal disturbances. Moreover, dexmedetomidine's pharmacological profile, including sedative and sympatholytic effects, promotes stable hemodynamics during surgery and postoperatively.

However, several considerations must be kept in mind when using intrathecal dexmedetomidine. Dosages should be carefully titrated based on individual patient factors such as age, weight, comorbidities, and the specific surgical procedure to minimize risks. While rare, there is a potential risk of neurotoxicity with intrathecal administration of dexmedetomidine, highlighting the importance of adhering to recommended dosages and guidelines for safe use. Continuous monitoring of vital signs, sedation levels, neurological status, and respiratory function is crucial to ensure patient safety and optimal outcomes during and after intrathecal dexmedetomidine administration.

Dexmedetomidine as a part of epidural anaesthesia:

Epidural administration of dexmedetomidine involves delivering the medication into the epidural space, near the spinal nerves, through a catheter placed by an anesthesiologist. This technique allows for localized anaesthesia and prolonged analgesia, making it beneficial for various procedures, especially those involving the lower abdomen, pelvis, or lower extremities.

The dosages of epidural dexmedetomidine depend on factors such as the patient's age, weight, medical condition, and the specific procedure. Typical dosages range from 1 to 10 micrograms, often mixed with a local anesthetic solution such as bupivacaine or ropivacaine before administration via the epidural catheter.

Epidural dexmedetomidine is commonly used for labor analgesia in obstetrics, providing effective pain relief during childbirth while minimizing maternal and fetal side effects. Additionally, it is utilized in surgical procedures requiring epidural anaesthesia or postoperative analgesia, such as abdominal surgeries, orthopedic procedures, and gynecological surgeries.

One of the key benefits of epidural dexmedetomidine is its ability to enhance the analgesic effect of local anesthetics, leading to prolonged and more effective pain relief compared to local anesthetics alone. By extending the duration of analgesia, epidural dexmedetomidine reduces the need for opioids postoperatively, thereby minimizing opioid-related side effects and improving recovery outcomes. Moreover, its pharmacological properties, including sedation and sympatholytic effects, contribute to stable hemodynamics during surgery and postoperative care.

Dosages of epidural dexmedetomidine should be carefully titrated based on individual patient factors and the desired level of anaesthesia and analgesia. Continuous monitoring of vital signs, sedation levels, neurological status, and respiratory function is essential during and after epidural dexmedetomidine administration to ensure patient safety and optimal pain management. While generally well-tolerated, epidural dexmedetomidine can occasionally lead to side effects such as hypotension, bradycardia, and sedation, requiring prompt recognition and intervention.

Rectal administration of dexmedetomidine as a part of procedural sedation:

Research on rectal administration of dexmedetomidine is limited compared to other routes like intravenous or epidural. However, there are some studies and case reports that have explored the potential use of rectal dexmedetomidine for sedation and analgesia in certain populations.

Rectal dexmedetomidine for paediatric sedation:

Many studies have investigated the efficacy and safety of rectal dexmedetomidine for sedation in paediatric patients undergoing minor surgical procedures. The results showed that rectal dexmedetomidine provided effective sedation with minimal adverse effects, making it a promising alternative to other routes of administration in paediatric anaesthesia. ^[21]

Topical dexmedetomidine for analgesia:

Topical dexmedetomidine, available in gel or patch formulations, has emerged as a promising option for pain management across various conditions due to its targeted analgesic effects. Studies have explored its efficacy in alleviating neuropathic pain, postoperative discomfort, and chronic musculoskeletal pain.

In neuropathic pain management, a study used a topical dexmedetomidine gel containing 0.1% dexmedetomidine applied three times daily to the affected area. Patients reported significant reductions in neuropathic pain intensity and improved quality of life. Similarly, in postoperative pain, research employed dexmedetomidine patches or gels applied directly to surgical incisions or wound sites, resulting in reduced pain scores and decreased opioid consumption post-surgery. Patch concentrations typically ranged from 4 to 10 micrograms per square centimeter, applied for a specified duration post-surgery. ^[22]

Chronic pain conditions like osteoarthritis or fibromyalgia have also been targeted with topical dexmedetomidine. Studies utilized gel concentrations ranging from 0.1% to 0.5% dexmedetomidine applied to joint areas or tender points, leading to improved pain relief and functional outcomes.

The localized analgesia provided by topical dexmedetomidine minimizes systemic effects and potential side effects associated with oral or intravenous medications. It also holds promise in reducing opioid use, thereby lowering the risk of opioid-related complications. Clinical studies have generally reported a favourable safety profile for topical dexmedetomidine, with minimal systemic absorption and adverse effects.

The topical dexmedetomidine offers a non-invasive and targeted approach to pain management, with dosages typically ranging from 0.1% to 0.5% dexmedetomidine in gel or patch formulations. Further research is needed to optimize dosing regimens, evaluate long-term efficacy, and explore its use in a wider range of pain syndromes.

Transdermal dexmedetomidine:

Dexmedetomidine transdermal patches have emerged as a promising method for providing sustained analgesia and sedation. These patches are applied to intact skin, allowing for gradual absorption of the medication into the bloodstream over an extended period. This sustained-

release delivery system offers continuous analgesia or sedation, making it suitable for managing chronic pain or providing prolonged sedation in clinical settings.

Dosages of dexmedetomidine in transdermal patches vary depending on the intended use. For pain management, the patches typically deliver doses ranging from 1 to 10 micrograms per hour, adjusted based on the patient's pain severity and individual response. In sedation applications, lower doses ranging from 0.1 to 1 microgram per hour may be used for purposes such as prolonged sedation in intensive care units (ICUs) or procedural sedation.

These transdermal patches are indicated for chronic pain management, including neuropathic pain, musculoskeletal pain, and cancer-related pain. Additionally, they find use in sedation for procedures and in non-operating room settings. The continuous and controlled delivery of dexmedetomidine through transdermal patches maintains stable plasma levels, providing sustained therapeutic effects.

One of the key benefits of dexmedetomidine transdermal patches is their ability to offer continuous delivery, minimizing fluctuations in drug levels and potentially reducing side effects such as hypotension or sedation depth variability. Patients may also benefit from the convenience of transdermal patches, especially for long-term pain management or sedation requirements, enhancing treatment adherence.

However, there are considerations to keep in mind when using dexmedetomidine patches. Proper skin preparation and rotation of patch sites help minimize the risk of skin irritation or allergic reactions. Dosing adjustments should be made cautiously, considering individual patient factors, concurrent medications, and the desired level of analgesia or sedation. Continuous monitoring of vital signs, sedation levels, and pain scores is crucial during dexmedetomidine patch administration to ensure optimal therapeutic outcomes and detect any adverse effects promptly.

Intra articular dexmedetomidine for postoperative analgesia:

Intra-articular dexmedetomidine administration has emerged as a promising strategy for providing effective postoperative analgesia, particularly in orthopedic surgeries involving joints. Dexmedetomidine, an alpha-2 adrenergic agonist, acts locally on pain pathways within the joint, leading to pain relief and decreased opioid consumption, which are key goals in modern pain management strategies.

Studies have investigated the use of intra-articular dexmedetomidine as an adjunct to local anesthetics in various orthopedic procedures, such as knee arthroscopy and shoulder surgeries. Dosages typically range from 25 to 100 micrograms, depending on factors like the specific joint involved and the complexity of the surgical intervention. This dose is often combined with a local anesthetic solution like bupivacaine or ropivacaine to achieve optimal pain control.^[23]

The benefits of intra-articular dexmedetomidine include enhanced analgesia, reduced opioid requirements, and improved functional recovery postoperatively. By augmenting the analgesic effects of local anesthetics, dexmedetomidine contributes to prolonged pain relief and minimizes opioid-related side effects such as respiratory depression, sedation, and

gastrointestinal disturbances. This not only improves patient comfort but also supports faster mobilization and rehabilitation, leading to better overall outcomes.

However, careful considerations must be taken into account when using intra-articular dexmedetomidine. Precise dosing and volume adjustments are necessary based on factors like the patient's age, weight, comorbidities, and the specific surgical procedure. Continuous monitoring of pain scores, vital signs, sedation levels, and opioid requirements is essential during the postoperative period to ensure optimal pain management and detect any adverse effects promptly.

Dexmedetomidine for wound infiltration:

Dexmedetomidine has been explored as an adjunct in wound infiltration techniques to enhance postoperative pain management. This approach involves the local administration of dexmedetomidine directly into the surgical site, typically in combination with local anesthetic agents. Studies have investigated the use of dexmedetomidine in wound infiltration for various surgical procedures, including abdominal surgeries, orthopedic interventions, and dermatological surgeries. The goal is to provide targeted analgesia at the surgical site, thereby reducing pain intensity and improving patient comfort during the immediate postoperative period. [24,25]

Dosages of dexmedetomidine used in wound infiltration vary based on factors such as the type of surgery, the extent of tissue trauma, and the desired duration of analgesia. Typically, concentrations ranging from 1 to 10 micrograms per millilitre are employed, often mixed with local anesthetic solutions like bupivacaine or lidocaine.

The benefits of dexmedetomidine wound infiltration include enhanced pain relief, reduced opioid consumption, and improved postoperative recovery. Dexmedetomidine's alpha-2 adrenergic agonist properties contribute to its analgesic effects by modulating pain signalling pathways locally, leading to prolonged and effective pain control.

One notable advantage of dexmedetomidine infiltration is its potential to spare systemic opioid use, thereby minimizing opioid-related side effects such as sedation, respiratory depression, and gastrointestinal disturbances. This is particularly advantageous in surgeries where opioid-sparing strategies are emphasized to improve patient outcomes and satisfaction. However, considerations should be given to proper dosing, patient selection, and monitoring during dexmedetomidine wound infiltration. Close attention to dosage calculations, local tissue toxicity, and potential systemic absorption is essential to ensure safe and effective pain management while avoiding adverse effects.

References:

1. Moller MH, Alhazzani W, Lewis K, Belley-Cote E, Granholm A, Centofanti J, McIntyre WB, et, al Use of dexmedetomidine for sedation in mechanically ventilated adult ICU patients: a rapid practice guideline. *Intensive Care Med.* 2022 Jul;48(7):801-810.
2. Lewis K, Alshamsi F, Carayannopoulos KL, Granholm A, Piticaru J, Al Duhailib Z, et al. GUIDE group. Dexmedetomidine vs other sedatives in critically ill mechanically

- ventilated adults: a systematic review and meta-analysis of randomized trials. *Intensive Care Med.* 2022 Jul;48(7):811-840
3. Peng K, Wu SR, Ji FH, Li J. Premedication with dexmedetomidine in paediatric patients: a systematic review and meta-analysis. *Clinics (Sao Paulo).* 2014 Nov;69(11):777-86
 4. Phan H, Nahata MC. Clinical uses of dexmedetomidine in paediatric patients. *Paediatr Drugs.* 2008;10(1):49-69][Mahmoud M, Barbi E, Mason KP. Dexmedetomidine: What's New for Paediatrics? A Narrative Review. *J Clin Med.* 2020 Aug 24;9(9):2724.
 5. Bae HB. Dexmedetomidine: an attractive adjunct to anaesthesia. *Korean J Anesthesiol.* 2017 Aug;70(4):375-376
 6. Menda F, Köner O, Sayin M, Türe H, Imer P, Aykaç B. Dexmedetomidine as an adjunct to anesthetic induction to attenuate hemodynamic response to endotracheal intubation in patients undergoing fast-track CABG. *Ann Card Anaesth.* 2010 Jan-Apr;13(1):16-21
 7. Memiş D, Turan A, Karamanlioğlu B, Pamukçu Z, Kurt I. Adding dexmedetomidine to lidocaine for intravenous regional anaesthesia. *Anesth Analg.* 2004 Mar;98(3):835-40, table of contents
 8. Gupta M, Rohilla R, Gupta P, Tamilchelvan H, Joshi U, Kanwat J. Nebulized dexmedetomidine for attenuating hemodynamic response to laryngoscopy and endotracheal intubation in adult patients undergoing surgeries under general anaesthesia: a systematic review and meta-analysis of randomized controlled trials. *BMC Anesthesiol.* 2023 Dec 11;23(1):406
 9. Misra S, Behera BK, Mitra JK, Sahoo AK, Jena SS, Srinivasan A. Effect of preoperative dexmedetomidine nebulization on the hemodynamic response to laryngoscopy and intubation: a randomized control trial. *Korean J Anesthesiol.* 2021 Apr;74(2):150-157
 10. Shrivastava P, Kumar M, Verma S, Sharma R, Kumar R, Ranjan R, Prakash J. Evaluation of Nebulised Dexmedetomidine Given Pre-operatively to Attenuate Hemodynamic Response to Laryngoscopy and Endotracheal Intubation: A Randomised Control Trial. *Cureus.* 2022 May 22;14(5):e25223
 11. Rao S, Rajan N. Dexmedetomidine as an Adjunct for Regional Anesthetic Nerve Blocks. *Curr Pain Headache Rep.* 2021 Feb 3;25(2):8
 12. Bao N, Shi K, Wu Y, He Y, Chen Z, Gao Y, et al. Dexmedetomidine prolongs the duration of local anesthetics when used as an adjuvant through both perineural and systemic mechanisms: a prospective randomized double-blinded trial. *BMC Anesthesiol.* 2022 Jun 7;22(1):176
 13. Xiao R, Liu LF, Luo YR, Liu C, Jin XB, Zhou W, et al. Dexmedetomidine Combined with Femoral Nerve Block Provides Effective Analgesia Similar to Femoral Nerve Combined with Sciatic Nerve Block in Patients Undergoing Total Knee Arthroplasty: A Randomized Controlled Study. *Drug Des Devel Ther.* 2022 Jan 13;16:155-164
 14. Sajid B, Mohamed T, Jumaila M. A comparison of oral dexmedetomidine and oral midazolam as premedicants in children. *J Anaesthesiol Clin Pharmacol.* 2019 Jan-Mar;35(1):36-40.
 15. Shailaja S, Ray A, Ray S, Kirubakaran R. Dexmedetomidine for procedural sedation in children. *Cochrane Database Syst Rev.* 2017 Feb 14;2017(2):CD010886
 16. Olgun G, Ali MH. Use of Intranasal Dexmedetomidine as a Solo Sedative for MRI of Infants. *Hosp Pediatr.* 2018 Jan 23;hpeds.2017-0120

17. Morse JD, Cortinez LI. Dexmedetomidine dosing for procedural sedation in children and adults: We can do better. *Paediatr Anaesth*. 2024 May;34(5):391-393
18. Liu X, Li Y, Kang L, Wang Q. Recent Advances in the Clinical Value and Potential of Dexmedetomidine. *J Inflamm Res*. 2021 Dec 30;14:7507-7527
19. Behrle N, Birisci E, Anderson J, Schroeder S, Dalabih A. Intranasal Dexmedetomidine as a Sedative for Paediatric Procedural Sedation. *J Pediatr Pharmacol Ther*. 2017 Jan-Feb;22(1):4-8
20. Sinnott J, Holthaus CV, Ablordeppey E, Wessman BT, Roberts BW, Fuller BM. The Use of Dexmedetomidine in the Emergency Department: A Cohort Study. *West J Emerg Med*. 2021 Aug 22;22(5):1202-1209
21. Kaur M, Singh PM. Current role of dexmedetomidine in clinical anaesthesia and intensive care. *Anesth Essays Res*. 2011 Jul-Dec;5(2):128-33
22. Zhao Y, He J, Yu N, Jia C, Wang S. Mechanisms of Dexmedetomidine in Neuropathic Pain. *Front Neurosci*. 2020 May 5;14:330
23. Paul S, Bhattacharjee DP, Ghosh S, Dawn S, Chatterjee N. Efficacy of intra-articular dexmedetomidine for postoperative analgesia in arthroscopic knee surgery. *Ceylon Med J*. 2010 Dec;55(4):111-5
24. Dong H, Liu H, Zhu D, Ruan B, Yu H, Xu X, Wang Y. Wound infiltration of dexmedetomidine as an adjunct to local anaesthesia in postoperative analgesia for lumbar surgery. *Minerva Anesthesiol*. 2021 Sep;87(9):1034-1041
25. Bhardwaj S, Devgan S, Sood D, Katyal S. Comparison of Local Wound Infiltration with Ropivacaine Alone or Ropivacaine Plus Dexmedetomidine for Postoperative Pain Relief after Lower Segment Cesarean Section. *Anesth Essays Res*. 2017 Oct-Dec;11(4):940-945

Submitted: 15/04/2024

Revised: 21/04/2024

Accepted: 30/04/2024

Published: 02/06/2024

Cite this article:

K Sohith Reddy, Dr. Major Priyank Sen, Dr. Sanjay Ashwamedh Kshirsagar, Dr. Hemangi Yashwant Jadhav, Dr. Safdhar Hasmi. R. Dexmedetomedine and Its Use in Different Routes – A Review. *Jour Med Dent Fron*, 01(Suppl 1), S1-S22, January 2024.